Life Sciences and Healthcare Consulting Services

Improving patient lives by helping clients discover, develop and bring new treatments and devices to market.

Talk to our experts
Life Sciences and Healthcare Consulting Services

Our passion is to partner with clients to achieve their strategic goals in delivering safe, effective and commercially successful treatments to patients faster. Throughout the Biopharma and MedTech product lifecycle, Clarivate consultants provide end-to-end solutions and transformative intelligence, using industry-leading products like Cortellis and Real World Data.

Our teams fuel innovation in Research and Development, Commercial Strategy, Evidence and Value, Technology and are right by your side as you improve patient lives and create a healthier tomorrow.

0 +

highly skilled consultants & analysts worldwide

0 +

years track record as a transformational, trusted industry partner

0 %

of world's top 50 pharma organization use our expertise


A pharma story from the heart of Europe

How Gedeon Richter partnered with Clarivate consultants to transform regulatory workflow

Read the case study

Research and

We help companies advance their drug discovery, preclinical proof-of-concept, and regulatory activities. Clarivate’s translational science expertise, skilled teams of regulatory and commercial experts and assets such as the Centre for Medicine Research (CMR) combine to offer a highly reputable source of pharmaceutical industry metrics and insights. By providing perspective, data and insights across the development spectrum, we complement client teams in generating long term value.

Commercial strategy

Our deep domain expertise and data-driven analysis provides customized, actionable solutions for our clients in the areas of new product planning, portfolio strategy, pricing, and market access. Leveraging Clarivate proprietary data, real world evidence and deep consulting expertise we can help you make faster, more informed strategic decisions on your toughest challenges and most significant opportunities.

Evidence, value, and access

We provide integrated health economics and outcomes research, value communications, and real world evidence strategy to the life science industry, partnering with client teams over the lifecycle of a brand. Our team consists of technical experts including health economists, statisticians, medical writers, in-house graphic designers, commercial assessment analysts, systematic reviewers, and COA specialists, enabling us to provide bespoke, end-to-end solutions across the product lifecycle.


We offer highly customized, use-case-specific data deliveries including bespoke databases, data files, and workflow solutions built to exact specifications. Innovative solutions such as the Clarivate Regulatory Intelligence Tracker (a companion of Cortellis Regulatory Intelligence) provide decision support to key business leaders leveraging internal and external data assets. Our team of experts and their proven methodologies create unique tools that allow clients to make data-driven decisions with speed and certainty across the drug/device development lifecycle.

​Real World Evidence

Our consultants provide and interpret best in class medical claims, offering a deeper view into US and international patient care and reimbursement information across inpatient and outpatient settings. We combine robust methodologies, deep therapy area and data science expertise with longitudinal and connected life sciences-grade real world data to accelerate your strategy. Services include aiding in data utilization, guiding through disease-specific nuances, or overseeing integrations. We are adaptable and well-organized to meet clients’ requirements – from delivering standardized dashboards to integrating and mastering our RWD with Clarivate formulary, affiliations or provider mapping data, so you can act with confidence.

“The fundamentals underpinning the biopharma sector have never been stronger, with new technologies fueling medical advancements and providing treatment options to patients with previously unmet needs. Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year’s Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes.”​

Mike Ward, Global Head of Thought Leadership, Life Sciences and Healthcare


What sets the Drugs to Watch in 2024 apart

From CRISPR to bispecifics, cancer to COPD, new drugs on the cusp

Our latest thought leadership

Let's talk

Learn how Clarivate consultants can provide the insight and foresight across your drug and device lifecycle.

Get in touch